The Latest Psychedelic Industry Statistics Explained
The global legal psychedelics market size was valued at USD 4.75 billion in 2020.
The statistic that the global legal psychedelics market size was valued at USD 4.75 billion in 2020 signifies the total monetary value of legal psychedelic substances that were bought and sold worldwide during that year. This figure includes various products such as psilocybin, MDMA, and ketamine that are used for therapeutic or medical purposes in accordance with legal regulations in different countries. The market size of USD 4.75 billion suggests a growing interest in psychedelic therapies and a potential shift in societal attitudes towards the use of these substances for mental health treatment and personal growth. This statistic provides insights into the economic significance of the legal psychedelics industry and its potential for further growth and development in the future.
The psychedelic drugs market size will likely exhibit a compound annual growth rate of 16.3% from 2021 to 2028.
The statistic indicates that the market size of psychedelic drugs is projected to experience significant growth over the period from 2021 to 2028, with a compound annual growth rate (CAGR) of 16.3%. This means that the industry is expected to expand at an average annual rate of 16.3% during this timeframe. Such a high growth rate suggests a strong market demand for psychedelic drugs, potentially driven by factors such as increasing research into their therapeutic benefits, changing societal attitudes towards mental health treatment, and regulatory changes that could facilitate their use. Investors and stakeholders in the psychedelic drugs market may view this CAGR forecast as a positive sign of potential opportunities for growth and profitability in the industry.
The North American legal psychedelics market took up a 35.7% share in 2020.
The statistic that the North American legal psychedelics market captured a 35.7% share in 2020 indicates the proportion of the total legal psychedelics market that was attributed to North America during that year. This suggests that North America had a significant presence in the emerging legal psychedelics industry, accounting for more than a third of the market. Factors such as changing perceptions of psychedelics for therapeutic use, ongoing legislative developments, and increasing consumer demand likely contributed to the growth of this market share. Monitoring this statistic over time can provide insights into the evolving landscape of the legal psychedelics industry and the regional dynamics shaping its development.
By 2028, the global legal psychedelics market size is predicted to be USD 10.75 billion.
The statistic states that the global legal psychedelics market size is anticipated to reach USD 10.75 billion by the year 2028. This prediction suggests a significant growth in the market for legal psychedelics, which are substances known for their mind-altering properties and potential therapeutic benefits. The projected value indicates a rise in demand for these products, likely due to evolving attitudes towards mental health treatments and increased research highlighting the potential uses of psychedelics in addressing various conditions. This forecast provides insights into the expected economic impact and development within the legal psychedelics industry over the next few years.
In 2019, the MDMA and LSD product segment accounted for a major share in the psychedelic drugs market at 33.0%.
The statistic suggests that in 2019, the market for psychedelic drugs was dominated by the MDMA and LSD product segment, which collectively held a significant share of 33.0%. This indicates that consumers and users of psychedelic drugs showed a preference for MDMA and LSD over other psychedelic substances during that time period. The high market share of this segment underscores the popularity and demand for these specific types of psychedelic drugs, potentially driven by various factors such as recreational use, therapeutic purposes, or cultural trends. The statistic indicates the importance and prominence of MDMA and LSD within the psychedelic drugs market landscape in 2019.
More than 70 clinics within the U.S. and Canada alone are conducting clinical trials on psychedelic drugs.
The statistic that more than 70 clinics within the U.S. and Canada alone are conducting clinical trials on psychedelic drugs indicates a growing interest and investment in researching the therapeutic potential of these substances. This suggests a shift in attitudes towards psychedelic drugs, moving away from their historical association with recreational use towards exploring their possible medical applications. The increasing number of clinics conducting such trials reflects a notable level of activity and legitimacy within the scientific and medical communities regarding the investigation of psychedelic compounds for treating conditions such as depression, PTSD, and addiction. This statistic underscores the importance of continuing research in this area to better understand the efficacy and safety of psychedelic therapies.
There are over 75 psychedelic investment opportunities in the world.
The statistic “There are over 75 psychedelic investment opportunities in the world” conveys that there are various investment prospects available in the growing market of psychedelic medicine and therapies. This statistic suggests a significant number of companies or projects related to psychedelic research, drug development, clinics, or other related ventures that offer potential for investors to participate in this emerging sector. As interest and acceptance of psychedelic substances increase for therapeutic and medical purposes, investors are presented with a wide range of opportunities to enter this market and potentially benefit from its growth and development.
By 2027, the global market size of psychedelic drugs is projected to exceed USD 10,264.9 million.
This statistic forecasts that the global market size for psychedelic drugs is expected to surpass USD 10,264.9 million by the year 2027. This indicates a significant growth trajectory in the market for psychedelic drugs, suggesting increasing interest, investment, and consumption in this sector over the coming years. Factors driving this projected growth may include expanding research into the therapeutic potential of psychedelic substances, changing societal attitudes toward mental health treatment, and regulatory shifts that potentially open up new pathways for the development and use of these drugs. Additionally, an increasing number of companies and investors are likely to capitalize on the potential profitability of psychedelic drugs, further contributing to the market expansion.
The number of legal psychedelic retreats increased by more than 50% between 2018 and 2019.
The statistic “The number of legal psychedelic retreats increased by more than 50% between 2018 and 2019” suggests a significant growth in the availability of legal psychedelic retreats within that time frame. This increase indicates a surging interest in and acceptance of the use of psychedelic substances for therapeutic and spiritual purposes. The rise in the number of these retreats by more than 50% signifies a notable expansion of this sector, which may reflect changing attitudes towards psychedelics and a growing demand for alternative forms of mental health treatment. This statistic highlights a noteworthy trend in the evolving landscape of psychedelic therapy and wellbeing practices.
Psychedelic retreats are predicted to be a $100 million industry by 2025.
The statistic indicating that psychedelic retreats are predicted to become a $100 million industry by 2025 suggests that there is a growing interest and potential for substantial financial growth in this sector. Psychedelic retreats typically refer to facilities or programs that offer guided psychedelic experiences for therapeutic, spiritual, or personal growth purposes. The prediction of a $100 million industry by 2025 highlights the increasing acceptance and recognition of the potential benefits of psychedelics in mental health treatment and personal development. This statistic implies that there is a significant market demand for psychedelic retreats and related services, reflecting a shift in societal attitudes towards psychedelics and alternative forms of therapy.
The legal psychedelic drugs’ market in Europe is estimated to grow at a CAGR of 15.4% through 2030.
The statistic indicates that the market for legal psychedelic drugs in Europe is projected to experience a Compound Annual Growth Rate (CAGR) of 15.4% from the present year until the year 2030. This forecast suggests a significant annual growth rate, highlighting a strong upward trend in the demand and consumption of legal psychedelic drugs within the European market over the coming decade. Factors contributing to this growth may include increasing acceptance and legalization of these substances for medical or therapeutic purposes, as well as evolving attitudes towards alternative treatments for mental health conditions. The statistic underscores the potential for expanding opportunities and investments within the legal psychedelic drugs market in Europe, indicating a promising industry outlook for the next ten years.
New York-based MindMed raised $24.2 million in its March 2020 IPO, creating a market cap of over $50 million.
In March 2020, the New York-based company MindMed conducted an initial public offering (IPO) and successfully raised $24.2 million from investors. This capital injection resulted in the company’s market capitalization exceeding $50 million, indicating the total value of all outstanding shares in the company. The market cap is a significant metric used by investors to gauge a company’s size and overall valuation in the financial markets. This successful IPO demonstrates investor confidence in MindMed’s business prospects and potential for growth in the future.
78% of patients reported improved wellbeing or life satisfaction after going through psychedelic-assisted psychotherapy.
The statistic that 78% of patients reported improved wellbeing or life satisfaction after undergoing psychedelic-assisted psychotherapy suggests a positive impact of this treatment approach on patient outcomes. This high percentage indicates a strong correlation between psychedelic-assisted psychotherapy and improvements in subjective well-being and life satisfaction among patients. The results highlight the potential effectiveness of this therapeutic intervention in addressing mental health issues and potentially enhancing overall quality of life for individuals who have undergone the treatment. These findings may have important implications for the field of mental health and could potentially inform future research and clinical practice in utilizing psychedelics as a tool in psychotherapeutic settings.
The UK is ranked third globally in terms of psychedelic research output, behind the USA and Switzerland.
The statistic indicates that the UK is the third-highest country in the world in terms of the amount of research output related to psychedelics, following the United States and Switzerland. This suggests that the UK is a significant contributor to the scientific exploration and study of psychedelics, alongside these two leading countries. The ranking highlights the UK’s active involvement in researching the potential therapeutic applications, risks, and benefits of psychedelics, which could have implications for various fields such as mental health, neuroscience, and pharmacology. This statistic underscores the global interest and investment in advancing our understanding of psychedelics and their impact on human health and society.
The global CAGR for Psilocybin is set to potentially reach 12.36% during 2020-2026.
The statement indicates that the Compound Annual Growth Rate (CAGR) for Psilocybin (the active compound in psychedelic mushrooms) is projected to be around 12.36% on a global scale between the years 2020 and 2026. This figure suggests the average annual growth rate of the psilocybin market over this period. A CAGR of 12.36% implies a significant growth trajectory, indicating a potentially expanding market for psilocybin products and services. This statistic could be driven by increasing acceptance and research into the therapeutic potential of psilocybin, leading to more investment and development in this sector.
There are over 20 U.S. states considering reforms to current psychedelic laws.
The statistic that over 20 U.S. states are considering reforms to current psychedelic laws indicates a significant and growing trend towards revisiting and potentially changing existing regulations around psychedelic substances. This suggests a shift in public opinion and policy towards exploring alternative approaches to addressing mental health issues, addictive behaviors, and other areas where psychedelics have shown potential therapeutic benefits. The fact that so many states are actively engaging with this topic signals a broader movement towards a more open and evidence-based discussion on the potential benefits and risks associated with psychedelics, potentially paving the way for changes in legislation and regulations in the near future.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.greenmarketreport.com
2. – https://www.www.globenewswire.com
3. – https://www.maps.org
4. – https://www.beckleyfoundation.org
5. – https://www.prohibitionpartners.com
6. – https://www.www.businessinsider.com
7. – https://www.www.fortunebusinessinsights.com
8. – https://www.psychedelicreview.com
